$MNMD
Mind Medicine (MindMed) Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023038057 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.20M $14.41M
YoY Change 43.31% 89.18%
% of Gross Profit
Research & Development $13.20M $14.78M
YoY Change 69.88% 58.45%
% of Gross Profit
Depreciation & Amortization $790.0K $790.0K
YoY Change 0.0% -3.66%
% of Gross Profit
Operating Expenses $21.62M $29.18M
YoY Change 27.28% 72.25%
Operating Profit -$21.62M -$29.18M
YoY Change 27.28% 72.25%
Interest Expense $720.0K $1.560M
YoY Change 44.58% -22385.71%
% of Operating Profit
Other Income/Expense, Net $3.693M $54.00K
YoY Change 641.57% -485.71%
Pretax Income -$17.92M -$29.13M
YoY Change 8.7% 71.79%
Income Tax
% Of Pretax Income
Net Earnings -$17.92M -$29.13M
YoY Change 8.72% 71.79%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$0.76
Diluted Earnings Per Share -$0.45 -$0.76
COMMON SHARES
Basic Shares Outstanding 39.72M 38.60M
Diluted Shares Outstanding 39.72M 38.58M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $117.7M $116.9M
YoY Change -23.83% 10.55%
Cash & Equivalents $117.7M $116.9M
Short-Term Investments
Other Short-Term Assets $2.400M $2.900M
YoY Change 20.54% -13.41%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $120.1M $119.8M
YoY Change -23.27% 9.81%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill $19.92M $19.92M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $229.0K $268.0K
YoY Change
Total Long-Term Assets $21.46M $22.29M
YoY Change -12.02% -11.49%
TOTAL ASSETS
Total Short-Term Assets $120.1M $119.8M
Total Long-Term Assets $21.46M $22.29M
Total Assets $141.6M $142.1M
YoY Change -21.76% 5.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.686M $8.577M
YoY Change 832.77% 1071.72%
Accrued Expenses $9.957M $9.950M
YoY Change 33.35% 39.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.15M $35.12M
YoY Change 19.65% 346.21%
LONG-TERM LIABILITIES
Long-Term Debt $14.07M $0.00
YoY Change
Other Long-Term Liabilities $349.0K $992.0K
YoY Change -72.65% -47.84%
Total Long-Term Liabilities $14.42M $992.0K
YoY Change 1029.86% -47.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.15M $35.12M
Total Long-Term Liabilities $14.42M $992.0K
Total Liabilities $45.57M $36.11M
YoY Change 66.84% 269.52%
SHAREHOLDERS EQUITY
Retained Earnings -$266.3M -$248.4M
YoY Change 40.45% 43.5%
Common Stock $361.5M $354.0M
YoY Change 5.58% 19.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $95.98M $106.0M
YoY Change
Total Liabilities & Shareholders Equity $141.6M $142.1M
YoY Change -21.76% 5.81%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$17.92M -$29.13M
YoY Change 8.72% 71.79%
Depreciation, Depletion And Amortization $790.0K $790.0K
YoY Change 0.0% -3.66%
Cash From Operating Activities -$16.62M -$13.85M
YoY Change 78.77% -8.44%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 17.40M 1.280M
YoY Change -70.11% 116.95%
NET CHANGE
Cash From Operating Activities -16.62M -13.85M
Cash From Investing Activities
Cash From Financing Activities 17.40M 1.280M
Net Change In Cash 780.0K -12.57M
YoY Change -98.41% -13.53%
FREE CASH FLOW
Cash From Operating Activities -$16.62M -$13.85M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001813814
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q2 us-gaap Warrants And Rights Outstanding Valuation Technique Extensible List
WarrantsAndRightsOutstandingValuationTechniqueExtensibleList
http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember
CY2022Q4 us-gaap Warrants And Rights Outstanding Valuation Technique Extensible List
WarrantsAndRightsOutstandingValuationTechniqueExtensibleList
http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40360
dei Entity Registrant Name
EntityRegistrantName
Mind Medicine (MindMed) Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1582538
dei Entity Address Address Line1
EntityAddressAddressLine1
One World Trade Center
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 8500
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10007
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
208-2454
dei Security12b Title
Security12bTitle
Common Shares, no par value per share
dei Trading Symbol
TradingSymbol
MNMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39716868
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116895000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142142000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2896000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3913000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
119791000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
146055000
CY2023Q2 us-gaap Goodwill
Goodwill
19918000
CY2022Q4 us-gaap Goodwill
Goodwill
19918000
CY2023Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2108000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
3689000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
268000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
331000
CY2023Q2 us-gaap Assets
Assets
142085000
CY2022Q4 us-gaap Assets
Assets
169993000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8577000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2111000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9950000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5877000
CY2023Q2 mnmd Financing Warrants Liability
FinancingWarrantsLiability
16594000
CY2022Q4 mnmd Financing Warrants Liability
FinancingWarrantsLiability
9904000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
35121000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17892000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
992000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1184000
CY2023Q2 us-gaap Liabilities
Liabilities
36113000
CY2022Q4 us-gaap Liabilities
Liabilities
19076000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38807159
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38807159
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37979136
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37979136
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
354023000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
344758000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
362000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
627000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248413000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194468000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
105972000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
150917000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
142085000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169993000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14777000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9326000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27375000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19567000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14407000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7617000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22670000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15881000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
29184000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
16943000
us-gaap Operating Expenses
OperatingExpenses
50045000
us-gaap Operating Expenses
OperatingExpenses
35448000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29184000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16943000
us-gaap Operating Income Loss
OperatingIncomeLoss
-50045000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35448000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1311000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
82000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2595000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
83000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
247000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-89000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
195000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-44000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1504000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6690000
CY2022Q2 us-gaap Other Income
OtherIncome
-7000
us-gaap Other Income
OtherIncome
1000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3900000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
40000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29130000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16957000
us-gaap Net Income Loss
NetIncomeLoss
-53945000
us-gaap Net Income Loss
NetIncomeLoss
-35408000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-279000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-147000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-265000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-196000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29409000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17104000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54210000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35604000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.6
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.6
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.26
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38576394
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38576394
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28242026
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28242026
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38329919
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38329919
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
123000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
407000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1857000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28196789
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28196789
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
150917000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1857000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7408000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54210000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
105972000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
151664000
mnmd Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
708000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
164000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
-407000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7979000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35604000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
124504000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
130344000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1274000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3763000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29409000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
105972000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
136805000
CY2022Q2 mnmd Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
590000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
41000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4172000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17104000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
124504000
us-gaap Profit Loss
ProfitLoss
-53945000
us-gaap Profit Loss
ProfitLoss
-35408000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7592000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8045000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1581000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
337000
mnmd Non Cash Lease Expense
NonCashLeaseExpense
28000
mnmd Non Cash Lease Expense
NonCashLeaseExpense
17000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6690000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1017000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-541000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-35000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6466000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3429000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3889000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
792000
mnmd Other Liabilities Long Term
OtherLiabilitiesLongTerm
192000
mnmd Other Liabilities Long Term
OtherLiabilitiesLongTerm
151000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27176000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27993000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1857000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
708000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
424000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-229000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25247000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27798000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142142000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
133539000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
116895000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
105741000
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION OF THE BUSINESS </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mind Medicine (MindMed) Inc. (the “Company” or “MindMed”) is incorporated under the laws of the Province of British Columbia. Its wholly owned subsidiaries, Mind Medicine, Inc. (“MindMed US”), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH are incorporated in Delaware, Delaware, Australia and Switzerland respectively. MindMed US was incorporated on May 30, 2019.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company’s mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. The Company is developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company’s lead product candidates.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of June 30, 2023, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">248.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Through June 30, 2023, all the Company’s financial support has primarily been provided by proceeds from the issuance of Common Shares and warrants to purchase Common Shares.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the Company continues its expansion, it may seek additional financing and/or strategic investments; however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of the issuance of these financial statements.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the condensed consolidated financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board standards’ effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an initial public offering or such earlier time that it is no longer an EGC.</span></p>
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248400000
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
110700000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
131700000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0
CY2022Q2 mnmd Indication Of Impairment Of Goodwill And Long Lived Assets
IndicationOfImpairmentOfGoodwillAndLongLivedAssets
0
CY2023Q2 mnmd Indication Of Impairment Of Goodwill And Long Lived Assets
IndicationOfImpairmentOfGoodwillAndLongLivedAssets
0
mnmd Indication Of Impairment Of Goodwill And Long Lived Assets
IndicationOfImpairmentOfGoodwillAndLongLivedAssets
0
mnmd Indication Of Impairment Of Goodwill And Long Lived Assets
IndicationOfImpairmentOfGoodwillAndLongLivedAssets
0
CY2022Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
9485000
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7377000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2108000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
9485000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5796000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3689000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000
CY2023Q2 mnmd Accrued Clinical And Manufacturing Costs
AccruedClinicalAndManufacturingCosts
3258000
CY2022Q4 mnmd Accrued Clinical And Manufacturing Costs
AccruedClinicalAndManufacturingCosts
605000
CY2023Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2818000
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3198000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1868000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
436000
CY2023Q2 mnmd Contribution Payable Current
ContributionPayableCurrent
1841000
CY2022Q4 mnmd Contribution Payable Current
ContributionPayableCurrent
1566000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
90000
CY2023Q2 mnmd Accrued Lease Liabilities Current
AccruedLeaseLiabilitiesCurrent
75000
CY2022Q4 mnmd Accrued Lease Liabilities Current
AccruedLeaseLiabilitiesCurrent
72000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9950000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5877000
CY2023Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q2 mnmd Common Stock Shares Issued And Outstanding
CommonStockSharesIssuedAndOutstanding
38807159
CY2022Q3 mnmd Common Share And Warrant Public Offering Expire Date
CommonShareAndWarrantPublicOfferingExpireDate
2027-09-30
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.38
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2190315
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.29
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4484000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
10137
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
25.43
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
56496
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
16.51
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2123682
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.49
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y8M12D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
43161000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1042480
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
25.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P3Y1M6D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4398000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
61558
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3842000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4253000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7592000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8045000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
12800000
CY2023Q2 us-gaap Other Commitment
OtherCommitment
37900000

Files In Submission

Name View Source Status
0000950170-23-038057-index-headers.html Edgar Link pending
0000950170-23-038057-index.html Edgar Link pending
0000950170-23-038057.txt Edgar Link pending
0000950170-23-038057-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mnmd-20230630.htm Edgar Link pending
mnmd-20230630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mnmd-20230630_cal.xml Edgar Link unprocessable
mnmd-20230630_def.xml Edgar Link unprocessable
mnmd-20230630_pre.xml Edgar Link unprocessable
mnmd-20230630_lab.xml Edgar Link unprocessable
mnmd-20230630_htm.xml Edgar Link completed
mnmd-ex10_2.htm Edgar Link pending
mnmd-ex10_3.htm Edgar Link pending
mnmd-ex31_1.htm Edgar Link pending
mnmd-ex31_2.htm Edgar Link pending
mnmd-ex32_1.htm Edgar Link pending
mnmd-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending